Power and sample-size analysis for the Royston–Parmar combined test in clinical trials with a time-to-event outcome
- 1 March 2018
- journal article
- research article
- Published by SAGE Publications in The Stata Journal: Promoting communications on statistics and Stata
- Vol. 18 (1) , 3-21
Abstract
Randomized controlled trials with a time-to-event outcome are usually designed and analyzed assuming proportional hazards (PH) of the treatment effect. The sample-size calculation is based on a log-rank test or the nearly identical Cox test, henceforth called the Cox/log-rank test. Nonproportional hazards (non-PH) has become more common in trials and is recognized as a potential threat to interpreting the trial treatment effect and the power of the log-rank test—hence to the success of the trial. To address the issue, in 2016, Royston and Parmar (BMC Medical Research Methodology 16: 16) proposed a “combined test” of the global null hypothesis of identical survival curves in each trial arm. The Cox/log-rank test is combined with a new test derived from the maximal standardized difference in restricted mean survival time (RMST) between the trial arms. The test statistic is based on evaluations of the between-arm difference in RMST over several preselected time points. The combined test involves the minimum p-value across the Cox/log-rank and RMST-based tests, appropriately standardized to have the correct distribution under the global null hypothesis. In this article, I introduce a new command, power_ct, that uses simulation to implement power and sample-size calculations for the combined test. power_ct supports designs with PH or non-PH of the treatment effect. I provide examples in which the power of the combined test is compared with that of the Cox/log-rank test under PH and non-PH scenarios. I conclude by offering guidance for sample-size calculations in time-to-event trials to allow for possible non-PH.Keywords
This publication has 17 references indexed in Scilit:
- Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazardsBMJ, 2017
- Strmst2 and Strmst2pw: New Commands to Compare Survival Curves Using the Restricted Mean Survival timeThe Stata Journal: Promoting communications on statistics and Stata, 2016
- Regression Analysis of Censored Data Using Pseudo-observations: An UpdateThe Stata Journal: Promoting communications on statistics and Stata, 2015
- Fitting and Modeling Cure in Population-Based Cancer Studies within the Framework of Flexible Parametric Survival ModelsThe Stata Journal: Promoting communications on statistics and Stata, 2012
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Further Development of Flexible Parametric Models for Survival AnalysisThe Stata Journal: Promoting communications on statistics and Stata, 2009
- Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-overStatistics in Medicine, 2006
- A Menu-driven Facility for Complex Sample Size Calculation in Randomized Controlled Trials with a Survival or a Binary Outcome: UpdateThe Stata Journal: Promoting communications on statistics and Stata, 2005
- Regression Analysis of Restricted Mean Survival Time Based on Pseudo-ObservationsLifetime Data Analysis, 2004
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996